Introduction
Cis-9,10-octadecanoamide (oleamide, ODA) is an endogenous sleep-inducing substance, first isolated from the cerebro-spinal fluid of sleep-deprived cats (Cravatt et al., 1995) . The primary amide of oleic acid, ODA is an endogenous fatty acid amide of the same family of chemical messengers that includes the endocannabinoid anandamide (AEA). Although its synthetic pathway is unclear, ODA has been shown to be produced in mouse brain microsomes (Sugiura et al., 1996) and mouse neuroblastoma cells where ODA was found to be 78 times more abundant than AEA . ODA is a preferred substrate for the serine hydrolase FAAH, the enzyme responsible for the hydrolysis of all fatty acid amides including AEA (Boger et al., 2000a) .
ODA has been shown to have various effects in vitro including inhibition of gap junction-mediated cell-cell communication (Boger et al., 1999) , modulation of 5-HT 1 , 5-HT 2A,C and 5-HT 7 receptors (Thomas et al., 1997; Hedlund et al., 1999) and modulation of inhibitory ionotropic receptors such as the GABA A receptor (Coyne et al., 2002) .
When administered in vivo, ODA produces similar effects to AEA. Both induce sleep, ODA increasing the slow wave sleep 2 (SWS2) phase (Cravatt et al., 1995; Boger et al., 1998; Yang et al., 1999; Huitron-Resendiz et al., 2001) and AEA increasing SWS2 and rapid eye movement (REM) sleep (MurilloRodriguez et al., 1998) . ODA induces the classic tetrad of behaviours, used to identify cannabinergic activity, with a similar activity profile to AEA . ODA produces a dose-dependent hypothermia and a decrease in locomotor activity in both mice and rats , Huitron-Resendiz et al., 2001 . ODA also induces catalepsy in mice but not in rats (Fedorova et al., 2001) and produces antinociception in both species Fedorova et al., 2001; Murillo-Rodriguez et al., 2001) . Studies using the selective CB 1 receptor antagonist SR141716A have yielded conflicting results. SR141716A has been shown to reverse the effects of ODA on sleep (Mendelson & Basile, 1999) , locomotor activity, ODA-potentiated 5-HT-mediated behaviours (Cheer et al., 1999) and antinociception (Fedorova et al., 2001 ) yet in a recent report failed to reverse locomotor activity and ptosis (Lichtman et al., 2002) . SR141716A failed to reverse ODAinduced hypothermia in both studies that examined the effect (Fedorova et al., 2001; Lichtman et al., 2002) . Further, Lichtman et al. (2002) investigated the ability of ODA to induce cannabinoid-like effects in CB 1 knockout mice. All three of the effects studied (hypolocomotion, hypothermia and ptosis) were induced by ODA in CB 1 knockout mice. However, the ability of ODA to induce sleep, analgesia or catalepsy in CB 1 knockout mice was not reported.
In vitro binding studies have also provided conflicting results. Boring et al. (1996) (Lichtman et al., 2002) or was unable to bind Sheskin et al., 1997) to either the CB 1 or CB 2 receptor at concentrations up to 10 mM. In order to explain the cannabinergic effects of ODA, with no apparent binding to the CB 1 receptor, an 'entourage' effect was suggested (Lambert & Di Marzo, 1999) . ODA may potentiate or prolong the effects of endocannabinoids such as AEA by competitively inhibiting the enzyme FAAH . A more recent study by Cheer et al. (1999) found that ODA inhibited [ 3 H]CP55,940 binding with an IC 50 of 10 mM (with an increase of affinity in the presence of the FAAH inhibitor phenylmethylsulphonyl fluoride) suggesting that ODA might indeed exert some effects directly via the CB 1 receptor.
Owing to the inconsistent nature of both the in vitro and in vivo findings, the involvement of cannabinoid receptors in the actions of ODA is disputed. In the present study, radioligand binding was used to determine the ability of ODA and AEA to bind to the CB 1 receptor in rat whole-brain membranes and ODA to human-CB 1 (hCB 1 ) transfected human embryonic kidney (HEK)-293T cells. The ability of ODA to bind to the human-CB 2 (hCB 2 ) receptor in transfected HEK-293T cells was also tested. The [ 35 S]GTPgS membrane binding assay was used to determine the ability of ODA to activate rat brain CB 1 receptors and was compared with two positive controls, HU210 and AEA. Receptor specificity was determined by performing the assay in the presence of selective CB 1 receptor antagonists. [
35 S]GTPgS autoradiography in rat brain sections was used to investigate the distribution of activated CB 1 receptors after exposure to ODA compared to the cannabinoid agonist HU210. Cyclic AMP (cAMP) accumulation assays were performed in N1E 115 cells, which endogenously express CB 1 receptors, to determine whether ODA inhibits adenylyl cyclase via the CB 1 receptor.
The data presented here indicate that ODA is a full endogenous cannabinoid receptor agonist with selectivity for the CB 1 receptor.
Some of the data presented have been communicated in preliminary form to the British Pharmacological Society (Ralevic et al., 2000; Leggett et al., 2002) .
Methods

Materials
HU210, AEA and ODA were obtained from Tocris Cookson, U.K. SR141716A was supplied via the NIMH synthesis programme (contract NOIMH30003) and LY320135 was a gift from Eli Lilly (U.S.A.). Pertussis toxin was obtained from Sigma (U.K.) and stored at À201C until required. Trans-ODA was a kind gift from Dr G. Lees (University of Sunderland). ODA and trans-ODA were made as stock solutions in ethanol or DMSO (10 mM) and stored at À201C until required. HU210, SR141716A and LY320135 were made as stock solutions in ethanol (10 mM) and stored at À201C until required.
Rat brain membrane preparation
Rats were killed by decapitation and brains (minus brainstem) were removed and rapidly homogenised in ice-cold Tris buffer (50 mM Tris, 100 mM NaCl, 10 mM MgCl 2 , pH 7.4). with a glass/teflon homogeniser. The homogenate was centrifuged at 20,000 Â g at 41C for 10 min and the pellet resuspended in Tris buffer. Homogenisation and centrifugation were repeated twice and the final pellet was resuspended in storage buffer (50 mM Tris, 1 mM EDTA, pH 7.4) to a protein concentration of 2 mg ml À1 for [ 35 S]GTPgS binding or 5 mg ml À1 for radioligand binding (Bradford, 1976) . hCB 1 and hCB 2 transient transfection and membrane preparation HEK-293T cells were grown in Dubelcco's modified Eagle's medium (DMEM) with 10% foetal bovine serum and high glucose. Cells were transiently transfected with pcDNA3 encoding CB 1 or CB 2 using calcium phosphate precipitation and used for membrane preparation as described previously (Abadji et al., 1999) . Briefly, at 24 h post-transfection, cells were harvested, washed twice in phosphate-buffered saline (PBS) and resuspended in PBS with 0.1% v v À1 protease inhibitor cocktail (Sigma Chemical Co., St Louis, MO, U.S.A.). Cell disruption was performed with nitrogen cavitation at 750 psi for 5 min. Following removal of cell debris and 254
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Oleamide is an endogenous CB 1 agonist nuclei by differential centrifugation, membranes were resuspended in TME buffer (25 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 1 mM EDTA) þ 7% sucrose. The membrane preparation was diluted to 0.6 mg ml À1 total protein concentration (Bradford, 1976) and stored at À701C.
Mouse neuroblastoma N1E 115 cell culture
Mouse neuroblastoma N1E 115 cells were grown to confluence in culture flasks and maintained in DMEM with 10% foetal calf serum at 371C in a humidified atmosphere containing 5% CO 2 . Cells were then diluted and distributed into 24-well plates to a final volume of 1 ml per well 72 h prior to incubation with [ (Pertwee, 1997) . Results are presented as mean values, with 95% confidence intervals.
Radioligand binding assays with HEK-293T membrane preparations containing hCB 1 and hCB 2 receptors Radioligand binding assays were performed as previously described (Abadji et al., 1999) . Membrane preparations were incubated with 4 nM [ 3 H]CP55,940 with varying concentrations of ODA. NSB was determined with 1 mM CP55,940. All conditions were prepared in triplicate. A Brandel cell harvester (Brandel Inc., Gaitherburg, MD, U.S.A.) was used to separate bound from unbound ligand and the former quantified by liquid scintillation counting. Results were analysed with Prism GraphPAD Software (GraphPAD Software, San Diego, CA, U.S.A.) as previously described [
S]GTPgS membrane binding
Membranes were preincubated with 100 mM GDP (ICN Biomedicals Inc., U.K.) and 1 mM theophylline (Sigma, U.K.) in assay buffer (50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl 2 containing 5 mg ml À1 BSA, pH 7.4) for 20 min at 301C. Assay tubes were prepared in triplicate using the same buffer containing 500 ml preincubated membranes, 0.4 nM [ 35 S]GTPgS (Amersham, U.K.) and the appropriate concentrations of drug. The NSB was determined using 100 mM nonradiolabelled GTPgS and 1 mM HU210 was included as a positive control. Tubes were incubated for 45 min at 301C. Free and bound [
35 S]GTPgS were separated by rapid filtration (using filter mats presoaked in Tris buffer (pH 7.4) containing 5% BSA) with ice-cold Tris buffer (pH 7.4). Data are presented as mean values, with 95% confidence intervals for experiments performed in triplicate. EC 50 and IC 50 values were determined using nonlinear regression analysis of concentration response curves using Graphpad Prism3.
[
S]GTPgS autoradiography
Rats were killed by decapitation and brains were rapidly removed and frozen on dry ice. Coronal brain sections (20 mM) were cut on a cryostat and thaw mounted onto glass microscope slides. Sections were preincubated with 100 mM GDP in buffer A (50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl 2 , pH 7. (Zhou & Song, 2001) were grown on 24-well plates in DMEM with 10% foetal calf serum at 371C in an atmosphere of 5% CO 2 and air. Cells were maintained at 371C throughout the experiment. After 48 h, [ 3 H]adenine was added to a final concentration of 74 kBq ml À1 and 300ng ml À1 pertussis toxin was added when appropriate. Cells were incubated for a further 24 h before being washed twice with Hank's HEPES buffer (HHB) pH7.4 and left to equilibrate for 15 min in 1 ml of HHB. Rolipram (10 mM) (phosphodiesterase inhibitor) was added to each well to reduce enzymatic breakdown of cAMP followed immediately by antagonist (if required). Cannabinoids or vehicle (HHB) were added after 5 min and allowed to incubate for a further 5 min before the addition of 10 ml forskolin to a final concentration of 10 mM or 10 ml vehicle (ethanol). Cells were incubated for 15 min before the reaction was terminated by the addition of 50 ml (1M) HCl. Samples (50 ml) were removed to determine total [ 
Autoradiography was used to investigate the regional distribution of specific [
35 S]GTPgS binding in the presence of ODA or the high potency cannabinoid agonist HU210. Four brain regions were examined quantitatively: the striatum, cortex, hippocampus and cerebellum. HU210 (1 mM) significantly increased [ 35 S]GTPgS binding to 360789% (Po0.05, n ¼ 6) of basal in the striatum, 244739% (Po0.05, n ¼ 6) in the cortex, 225731% (Po0.05, n ¼ 6) in the hippocampus and .1 mM HU210 plus 1 mM SR141716A, (d) 100 mM cis-ODA, (e) 10 mM cis-ODA plus 1 mM SR141716A, (f) 10 mM cis-ODA plus 10 mM LY320135, (g) 100 mM trans-ODA (significance levels: *Po0.01 compared to basal binding).
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Oleamide is an endogenous CB 1 agonist 257 287767% (Po0.05, n ¼ 5) in the cerebellum. ODA (10 mM) significantly increased [ 35 S]GTPgS binding to 294789% (Po0.05, n ¼ 6) in the striatum, 226741% (Po0.05, n ¼ 6) in the cortex, 196729% (Po0.05, n ¼ 6) in the hippocampus and 254773% (Po0.05, n ¼ 5) in the cerebellum (Figures 6  and 7) .
Effect of ODA on forskolin-stimulated cAMP generation (1 mM) significantly reduced forskolin-stimulated [ 3 H]cAMP accumulation reducing levels to 132719% of basal (P ¼ 0.05, n ¼ 11). ODA (10 mM) significantly inhibited cAMP generation to 122717% of basal levels (P ¼ 0.02, n ¼ 11). The selective CB 1 receptor antagonist SR141716A completely reversed the inhibitory effect of 10 mM ODA (P ¼ 0.0003, n ¼ 11) while having no significant effect when administered alone (Figure 8) . Pretreatment of cells with pertussis toxin (300 ng ml À1 ) completely abolished the inhibitory effect of ODA on forskolin-stimulated cAMP generation (Po0.001, n ¼ 6). In addition, pretreatment with pertussis toxin significantly elevated cAMP above non-pretreated levels in forskolintreated (Po0.05, n ¼ 6) and ODA-treated cells (Po0.05, n ¼ 6, Figure 9 ).
Discussion
ODA shares many characteristics with the endocannabinoid AEA. Both ODA and AEA are fatty acid amides produced endogenously in the brain (Di Marzo, 1998) and both are hydrolysed by FAAH (Boger et al., 2000a, b) . In vivo administration of ODA or AEA induces sleep that can be Inhibition of forskolin (Forsk)-stimulated cAMP generation in mouse neuroblastoma N1E 115 cells by 1 mM HU210 and 10 mM ODA and attenuation of ODA-mediated inhibition by the selective CB1 receptor antagonist SR141716A (1 mM). ODA, HU210 and SR141716A had no effect alone. þ þ ¼ Po0.01 compared to basal cAMP generation (n ¼ 11), * ¼ Po0.05 compared to forskolinstimulated cAMP generation (n ¼ 11).
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Oleamide is an endogenous CB 1 agonist reversed by SR141716A. ODA also produces the classical tetrad of behaviours associated with cannabinoid agonists with a similar profile to AEA . SR141716A has been shown to reverse the effects of ODA on catalepsy, hypolocomotion and analgesia but not hypothermia (Fedorova et al., 2001) . Lichtman et al. (2002) were, however, unable to reverse ODA-induced hypolocomotion in their study with the CB 1 antagonist. Similarly, SR141716A also fails to completely reverse elements of AEA pharmacology (Breivogel et al., 2001) . A recent study has also demonstrated the ability of ODA to induce certain cannabinoid-like effects (hypolocomotion, hypothermia and ptosis) in CB 1 receptor knockout mice. The endogenous cannabinoid AEA has also been shown to have residual behavioural effects and stimulates [ 35 S]GTPgS binding in CB 1 knockout mice (Di Marzo et al., 2000; Wiley & Martin, 2002) . This may be due to AEA activating multiple types of receptor: both CB 1 and CB 2 cannabinoid receptors, the VR 1 vanilloid receptor (Pertwee & Ross, 2002) and possibly a non-CB 1/2 cannabinoid receptor subtype (Mang et al., 2001) . Despite sharing functional similarities with endocannabinoids, radioligand binding studies indicated that ODA had a low affinity for the cannabinoid CB 1 receptor. ODA was found to bind with a K i of 44 mM in rat brain membranes (Boring et al., 1996) , negligibly (Lichtman et al., 2002) , not to bind at all , or more recently, to bind with an IC 50 of 10 mM in rat cerebellar membranes (Cheer et al., 1999) . Additionally, Boring et al. (1996) reported that ODA, at concentrations up to 1 mM, was unable to enhance GTPgS binding to rat brain membranes, indicating an inability to activate G-protein-coupled receptors (GPCRs).
Owing to the reported low affinity of ODA for the CB 1 receptor and the apparent inability of ODA to activate the CB 1 GPCR, an alternative explanation for its cannabinergic effects was required. One theory presented was that the effects of endocannabinoids are potentiated via the competitive inhibition, by ODA, of the enzyme FAAH; known as the entourage effect (Lambert & Di Marzo, 1999) . However, ODA concentrations of X5 mM are required to inhibit FAAH-mediated hydrolysis of AEA and a non-hydrolysable analogue of ODA proved to be no more effective at inhibiting AEA hydrolysis (Fedorova et al., 2001) . Recently, in a study using FAAH knockout mice, it was concluded that FAAH regulates but does not mediate the effects of fatty acid amides (such as ODA and AEA) in vivo (Lichtman et al., 2002) . Studies have indicated that ODA affects other neurotransmitter systems. ODA has been reported to modulate 5-HT 1A and 5-HT 2A/2C receptors (Huidobro-Toro & Harris, 1996; Thomas et al., 1997) and has been shown to act via an allosteric site on the 5-HT 7 receptor, thereby modulating receptor affinity (Hedlund et al., 1999) . Recently, several cannabinoid agonists (tetrahydrocannabinol (THC), WIN55,212-2, AEA, JWH-015 and CP55,940) have been shown to inhibit human 5-HT 3A receptors via an allosteric site (Barann et al., 2002) highlighting another similarity in the actions of ODA and endogenous (and classical) cannabinoids. However, a recent report suggests that ODA does not modulate serotonergic transmission in the CA1 pyramidal neurons of the hippocampus (Dougalis et al., 2004) and it has also been shown that 5-HT 1A and 5-HT 2C antagonists have no effect on ODA-induced hypothermia, locomotor activity, analgesia or anxiety in rats (Fedorova et al., 2001) . Cheer et al. (1999) reported a modulation of 5-HT 2 receptor affinity but with no effect on associated second messengers. ODA is also a nonselective modulator of inhibitory ionotropic receptors and has been shown to act indirectly via an allosteric site on the GABA A receptor (Coyne et al., 2002) . Recently, it has been shown that the GABA A receptor antagonist bicuculline reverses ODA-induced hypothermia and analgesia (Fedorova et al., 2001 ) and elimination of the b subunit of the GABA A receptor prevents ODA-induced sleep (Laposky et al., 2001) .
The radioligand binding results from the present study are similar to those found by Cheer et al. (1999) but contrast sharply with those of Boring et al. (1996 ), Lichtman et al. (2002 and Mechoulam et al. (1997) . Here ODA inhibited [ 3 H]CP55,940 binding in rat whole-brain membranes with a K i value of 1.14 mM (0.52-2.53 mM). This represents an affinity for ODA much closer to those previously calculated for AEA binding to various rat CB 1 -containing membranes (52 nM, Devane et al., 1992; 143 nM, Hillard et al., 1995; 44 nM, Petitet et al., 1996; 266 nM, Rinaldi-Carmona et al., 1996) rather than the approximate 800 fold difference between ODA and AEA reported by Boring et al. (1996) . Indeed, in the present study under the same experimental conditions, AEA was found to have an affinity of 428 nM (346-510 nM) a less than three-fold difference in affinity. ODA also inhibited binding of the selective CB 1 receptor antagonist [
3 H]SR141716A (K i ¼ 2.63 mM, 0.62-11.20 mM) to rat brain membranes, again demonstrating a relatively high affinity for the CB 1 receptor. ODA Figure 9 Inhibition of forskolin (Forsk)-stimulated cAMP generation in mouse neuroblastoma N1E 115 cells by 10 mM ODA and blockade of ODA-mediated inhibition by pretreatment with 300 ng ml À1 pertussis toxin (PTX). Pretreatment with PTX significantly increased cAMP accumulation in Forsk only and ODA only treated cells compared to respective non-pretreated cells. * ¼ Po0.05 compared to basal cAMP levels, ** ¼ Po0.001 compared to basal cAMP levels, þ ¼ Po 0.05 compared to Forskstimulated cAMP levels, $ ¼ Po0.05 compared to respective nonpretreated condition, $$ ¼ o0.001 compared to non-pretreated condition.
Oleamide is an endogenous CB 1 agonist 259 also successfully inhibited [ 3 H]CP55,940 binding in hCB 1 HEK-293T cell membranes, although with marginally less affinity (K i ¼ 8.14 mM). The affinity of AEA binding to transfected hCB 1 receptors was reported as 115 nM in HEK-293 cell membranes (Song & Bonner, 1996) , although lower binding affinities have been quoted for AEA binding to hCB 1 in other model cells (252 nM, Mechoulam and Pride, 1995; 543 nM Felder et al., 1995) .
ODA at concentrations up to 100 mM only partially displaced [
3 H]CP55,940 binding to hCB 2 receptors, suggesting little affinity for the hCB 2 receptor. It should be noted, however, that selectivity of various agonists for cannabinoid receptors has been reported to vary by more than 2000-fold depending upon the species and assay conditions used (Pertwee, 1997; Iwamura et al., 2001) .
The ability of ODA to bind to the CB 1 receptor does not necessarily infer agonist activity. Preliminary experiments using [
35 S]GTPgS autoradiography resulted in significantly increased binding in only the paraventricular nucleus of the hypothalamus, although this was reversed by SR141716A (Beckett et al., 1999) and Boring et al. (1996) failed to observe any ODA-stimulated GTPgS binding in rat brain membranes at concentrations up to 1 mM. However, in the present study ODA enhanced [
35 S]GTPgS binding in rat whole-brain membranes in a stereoselective manner with an EC 50 of 1.64 mM, a 10-fold lower EC 50 than AEA under the same conditions. SR141716A concentration-dependently inhibited the increase in ODA-stimulated [
35 S]GTPgS binding, further indicating the effects of ODA to be mediated via the CB 1 receptor.
Although the distribution of ODA-induced increases in Fos protein and c-fos mRNA have been studied (Figure 7 ). This is consistent with ODA activating the same set of receptors as the cannabinoid HU210.
Since the evidence for ODA binding to and activating the CB 1 receptor may be considered controversial, its ability to inhibit cAMP generation via the CB 1 receptor would help to confirm its status as an endogenous cannabinoid agonist. Consistent with a previous report (Zhou & Song, 2001) ODAmediated attenuation of cAMP accumulation was completely reversed by 1 mM SR141716A and inactivation of G i/o GPCRs by pretreatment with pertussis toxin (PTX) also completely reversed the inhibitory effect of ODA. These results indicate strongly that the cAMP attenuation is mediated via a G i/olinked GPCR likely to be a CB 1 receptor. Interestingly, PTX treatment had the effect of unmasking a lesser, stimulatory effect of ODA on cAMP generation. Similar cryptic positive coupling of CB 1 receptors to adenylyl cyclase has been reported in striatal neurons and CB 1 -transfected Chinese hamster ovary cells after G i/o inactivation with PTX (Glass & Felder, 1997; Felder et al., 1998) .
It is difficult to reconcile previous reports of a lack of effect of ODA on CB 1 receptors with the present data, although methodological factors may be responsible for some of the differences. The most likely of these is the difficulty in dissolving ODA into saline-based buffers at concentrations higher than 300 mM. Indeed, we were unable to dissolve ODA at any final assay concentration higher than this without an unacceptable increase in the concentration of nonaqueous solvent (DMSO or ethanol) . Other factors such as buffer composition, temperature, rat strain and analytical methods may also have contributed to a difference in results. Similar methodological factors may account for the difference in agonist activity, as measured by GTPgS binding, in the present study compared to that reported by Boring et al. (1996) . It should be noted that even well-recognised cannabinoid agonists such as THC and AEA have been reported not to enhance [ 35 S]GTPgS binding in membrane preparations (Griffin et al., 1998) , a finding that has been negated by the weight of subsequent positive findings.
The apparent ability of ODA to induce certain behaviours in CB 1 knockout mice (Lichtman et al., 2002) may be due to interactions with other non-cannabinoid receptors, similar to those produced by a range of cannabinoid receptor agonists, or possibly with as yet uncharacterised cannabinoid receptor subtypes. ODA allosterically modulates GABA A receptors (Coyne et al., 2002) and bicuculline, a GABA A antagonist, reverses ODA-induced hypothermia (Fedorova et al., 2001 ). In addition, ODA allosterically modulates 5-HT receptors (Thomas et al., 1997) and established cannabinoid agonists have also been shown to act in this manner (Barann et al., 2002) . Therefore, in addition to allosteric and possibly, direct modulation of other receptor types and inhibition of FAAH, the effects of ODA may actually be mediated directly via the CB 1 receptor. Although the affinity of ODA for the CB 1 receptor is somewhat lower than that reported for AEA, it should be noted that the basal concentration of ODA in the brain has not yet been reliably measured. On the basis of the concentration of ODA in neuroblastoma cells being much higher than that of AEA , it is conceivable that endogenous levels of ODA might be sufficient to occupy a significant proportion of CB 1 receptors in situ and ODA may, therefore, act as a lowaffinity agonist.
In summary, the data presented clearly show that ODA occupies rat and human CB 1 (but not CB 2 ) receptors with micromolar affinity and that it has agonist activity comparable to that of HU210 and AEA, revealed by its ability to enhance GTPgS binding to membranes. Furthermore, ODA, at least in mouse neuroblastoma cells, can inhibit or stimulate (after G i/o inactivation) formation of the intracellular messenger cAMP in a CB 1 antagonist-sensitive fashion.
Thus, the evidence strongly supports the contention that ODA is a directly acting endogenous cannabinoid with selectivity for the CB 1 receptor.
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